IP Library › Granted Patent US 12,377,171
Granted Patent B2
US 12,377,171 · App. 18/205,751 · Granted Aug 5, 2025

Methods for treating and diagnosing blinding eye diseases

Inventor: Shelley Romayne Boyd (Toronto, CA)
Assignee: Translatum Medicus Inc.
A61K49/0034A61B3/102A61B3/1025A61B3/1233A61B3/1241A61K9/0019A61K9/0048A61K31/415A61K31/416A61K45/06A61K49/0008A61B2503/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,171
App. No.
18/205,751
Granted
Aug 5, 2025
Kind
B2
Abstract

This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).

Claims (23)

1. A method for treating dry age related macular degeneration (AMD) or reticular pseudodrusen (RPD) disease, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

each of R 1 and R 2 is independently H or a C1-C6 alkyl and

R 3 is H or a C1-C6 alkyl, wherein the pharmaceutical composition is formulated for intraocular, periocular, oral, or intra-vascular administration.

2. The method of claim 1 , wherein the compound of Formula I is bindarit.

3. The method of claim 1 , wherein the dry AMD is early stage AMD or atrophic AMD.

4. The method of claim 1 , wherein the method reduces the rate of progression to late disease.

5. The method of claim 1 , wherein the method reduces the rate of expansion of geographic atrophy.

6. The method of claim 1 , wherein the method reduces the onset of geographic atrophy.

7. The method of claim 6 , wherein the onset of geographic atrophy in the subject is assessed using optical coherence tomography (OCT).

8. The method of claim 1 , wherein the method comprises reducing the amount of pseudodrusen in the subject.

9. The method of claim 8 , wherein the method comprises reducing the amount of pseudodrusen in any one of the foveal area, perifoveal area, and juxtafoveal area of the subject's eye.

10. The method of claim 8 , wherein the reduction in the amount of pseudodrusen in the subject is assessed using optical coherence tomography (OCT).

11. The method of claim 1 , wherein the method comprises reducing expansion of pseudodrusen in the subject.

12. The method of claim 11 , wherein the method comprises reducing expansion of pseudodrusen in any one of the foveal area, perifoveal area, and juxtafoveal area of the subject's eye.

13. The method of claim 1 , wherein the method further comprises administering an additional therapeutic agent.

14. The method of 1 , wherein the pharmaceutical composition is formulated for sustained release.

15. A method for reducing the rate of expansion of geographic atrophy, progression to late AMD, or onset of atrophy in an eye of a subject afflicted with dry age related macular degeneration (AMD), comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

each of R 1 and R 2 is independently H or a C1-C6 alkyl and

R 3 is H or a C1-C6 alkyl, wherein the pharmaceutical composition is formulated for intraocular, periocular, oral, or intra-vascular administration.

16. The method of claim 15 , wherein the compound of Formula I is bindarit.

17. The method of 16 , wherein the pharmaceutical composition is formulated for sustained release.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2025
From: BOYD, SHELLEY ROMAYNE
To: TRANSLATUM MEDICUS INC.
Reel/Frame 070613/0837 →
Continuity (11)
Continuation 17392453 · Aug 3, 2021
Continuation 16695918 · Nov 26, 2019
Continuation 15937263 · Mar 27, 2018
Continuation 15603729 · May 24, 2017
Continuation 15485997 · Apr 12, 2017
Continuation 14636639 · Mar 3, 2015
Continuation 13838473 · Mar 15, 2013
Provisional Application 61693226 · Aug 24, 2012
Provisional Application 61641393 · May 2, 2012
Provisional Application 61640854 · May 1, 2012
Related Publication 20230405152A1 · Dec 21, 2023
References Cited (96)
US 4451477A · Silvestrini et al. · 1984 [cited by applicant]
US 1999367A · Baiocchi et al. · 1991 [cited by applicant]
US 5112986A · Baiocchi et al. · 1992 [cited by applicant]
US 5278183A · Silvestrini · 1994 [cited by applicant]
US 6020356A · Guglielmotti et al. · 2000 [cited by applicant]
US 6093743A · Lai et al. · 2000 [cited by applicant]
US 6274627B1 · Lai et al. · 2001 [cited by applicant]
US 6316502B1 · Lai et al. · 2001 [cited by applicant]
US 6319517B1 · Cavallo et al. · 2001 [cited by applicant]
US 6337087B1 · Cavallo et al. · 2002 [cited by applicant]
US 6534534B1 · Guglielmotti et al. · 2003 [cited by applicant]
US 6589991B1 · Lai et al. · 2003 [cited by applicant]
US 6596770B2 · Lai et al. · 2003 [cited by applicant]
US 6649591B2 · Lai · 2003 [cited by applicant]
US 6673908B1 · Stanton, Jr. · 2004 [cited by applicant]
US 7553496B2 · Ambati · 2009 [cited by applicant]
US 7732162B2 · Hoffman et al. · 2010 [cited by applicant]
US 7816497B2 · Ambati · 2010 [cited by applicant]
US 7928284B2 · Ambati · 2011 [cited by applicant]
US 8008092B2 · Ambati · 2011 [cited by applicant]
US 8067031B2 · Daniloff et al. · 2011 [cited by applicant]
US 8158152B2 · Palepu · 2012 [cited by applicant]
US 8198310B2 · Guglielmotti et al. · 2012 [cited by applicant]
US 8232265B2 · Rogers et al. · 2012 [cited by applicant]
US 8835481B2 · Guglielmotti · 2014 [cited by examiner]
US 8999292B2 · Boyd · 2015 [cited by examiner]
US 9370484B2 · Boyd · 2016 [cited by examiner]
US 9820969B2 · Boyd · 2017 [cited by examiner]
US 10265418B2 · Boyd · 2019 [cited by examiner]
US 10420848B2 · Boyd · 2019 [cited by examiner]
US 10537647B2 · Boyd · 2020 [cited by examiner]
US 10646592B2 · Boyd · 2020 [cited by examiner]
US 11110184B2 · Boyd · 2021 [cited by examiner]
US 11992534B2 · Boyd · 2024 [cited by examiner]
US 20030207309A1 · Hageman et al. · 2003 [cited by applicant]
US 20040177387A1 · Jayakrishna · 2004 [cited by applicant]
US 20060067935A1 · Ambati · 2006 [cited by applicant]
US 20060135423A1 · Ambati · 2006 [cited by applicant]
US 20060263409A1 · Peyman · 2006 [cited by applicant]
US 20070190055A1 · Ambati · 2007 [cited by applicant]
US 20070191273A1 · Ambati · 2007 [cited by applicant]
US 20080299130A1 · Ambati · 2008 [cited by applicant]
US 20090123375A1 · Ambati · 2009 [cited by applicant]
US 20090186376A1 · Ambati et al. · 2009 [cited by applicant]
US 20090260091A1 · Ambati · 2009 [cited by applicant]
US 20110097390A1 · Ambati · 2011 [cited by applicant]
US 20110182908A1 · Hageman et al. · 2011 [cited by applicant]
US 20110268723A1 · Ambati · 2011 [cited by applicant]
US 20120064010A1 · Ambati et al. · 2012 [cited by applicant]
EP 0131317 · 1985 [cited by applicant]
WO WO9716185 · 1997 [cited by applicant]
WO WO9836735 · 1998 [cited by applicant]
WO WO9836736 · 1998 [cited by applicant]
WO WO2004041160 · 2004 [cited by applicant]
WO WO2005108431 · 2005 [cited by applicant]
WO WO2007098113 · 2007 [cited by applicant]
WO WO2007133800 · 2007 [cited by applicant]
WO WO2008061671 · 2008 [cited by applicant]
WO WO2009105260 · 2009 [cited by applicant]
WO WO2010138591 · 2010 [cited by applicant]
WO WO2011036047 · 2011 [cited by applicant]
WO WO2011153234 · 2011 [cited by applicant]
WO WO2013163758 · 2013 [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/CA2013/050335, mailed Aug. 23, 2013, 12 pages. [cited by applicant]
Arnold, J. J. et al., “Reticular Pseudodrusen. A Risk Factor in Age-Related Maculopathy,” Retina 15:183-191 (1995). [cited by applicant]
Beckmann, N. et al., “In vivo visualization of macrophage infiltration and activity in inflammation using magnetic resonance imaging,” WIREs Nanomed. Nanobiotechnol. 1:272-298 (2009). [cited by applicant]
Bindewald, A. et al., “Classification of abnormal fundus autofluorescence patterns in the junctional zone of geographic atrophy in patients with age related macular degeneration,” Br. J. Ophthalmol. 89:874-878 (2005). [cited by applicant]
Bindewald, A. et al., “Classification of Fundus Autofluorescence Patterns in Early Age-Related Macular Disease,” Invest. Ophthalmol, Vis. Sci. 46:3309-3314 (2005). [cited by applicant]
Boretsky, A. et al., “Quantitative Evaluation of Retinal Response to Laser Photocoagulation Using Dual-Wavelength Fundus Autofluorescence Imaging in a Small Animal Model,” Invest. Ophthalmol. Vis. Sci. 52:6300-6307 (201… [cited by applicant]
Boyd, S. R. et al., “Reticular Fundus Autofluorescence (FAF) In The Evolution Of Geographic Atrophy (GA) In A Rat Model Of RPE Toxicity,” 2012 ARVO Annual Meeting, Abstract of Program#/Poster# 6504/A430, 2 pages (May 10… [cited by applicant]
Buono, C. et al., “Fluorescent pegylated nanoparticles demonstrate fluid-phase pinocytosis by macrophages in mouse atherosclerotic lesions,” J. Clin. Invest. 119(5):1373-1381 (2009). [cited by applicant]
Cone, R. E. et al., “Regulation Of Experimental Autoimmune Uveitis (EAU) Induction In Mice By The Phosphodiesterase Inhibitor Dipyrimidol And Of Active EAU By Bindarit, An Inhibitor Of Monocyte Chemotactic Proteins,” 20… [cited by applicant]
Duker, J. S., “The complete trial for dry AMD: Results,” Review of Ophthalmology, Sep. 6, 2012, 3 pages. [cited by applicant]
Enzmann, V. et al., “Behavioral and anatomical abnormalities in a sodium iodate-induced model of retinal pigment epithelium degeneration,” Exp. Eye Res. 82:441-448 (2006). [cited by applicant]
Eter, N. et al., “In Vivo Visualization of Dendritic Cells, Macrophages, and Microglial Cells Responding to Laser-Induced Damage in the Fundus of the Eye,” Invest. Ophthalmol. Vis. Sci. 49(8):3649-3658 (2008). [cited by applicant]
Fleckenstein, M. et al., “Fundus Autofluorescence and Spectral-Domain Optical Coherence Tomography Characteristics in a Rapidly Progressing Form of Geographic Atrophy,” Invest. Ophthalmol. Vis. Sci. 52(6):3761-3766 (201… [cited by applicant]
Franco, L. M. et al., “Decreased Visual Function after Patchy Loss of Retinal Pigment Epithelium Induced by Low-Dose Sodium lodate,” Invest. Ophthalmol. Vis. Sci. 50(8):4004-4010 (2009). [cited by applicant]
Kiuchi, K. et al., “Morphologic characteristics of retinal degeneration induced by sodium iodate in mice,” Curr, Eye Res. 25(6):373-379 (2002). [cited by applicant]
Ladewig, M. S. et al., “Prostaglandin E1 infusion therapy in dry age-related macular degeneration,” Prostaglandins, eukotrienes and Essential Fatty Acids, 72:251-256 (2005). [cited by applicant]
Lois, N. et al., “Fundus Autofluorescence in Patients With Age-related Macular Degeneration and High Risk of Visual Loss,” Am. J. Ophthalmol. 133:341-349 (2002)). [cited by applicant]
Luhmann, U. F. O. et al., “The Drusenlike Phenotype in Aging Ccl2-Knockout Mice Is Caused by an Accelerated Accumulation of Swollen Autofluorescent Subretinal Macrophages,” Invest. Ophthalmol. Vis. Sci. 50:5934-5943 (20… [cited by applicant]
Mendes-Jorge, L. et al., “Scavenger Function of Resident Autofluorescent Perivascular Macrophages and Their Contribution to the Maintenance of the Blood-Retinal Barrier,” Invest. Ophthalmol. Vis. Sci. 50(12):5997-6005 (… [cited by applicant]
Mizota, A. et al., “Functional Recovery of Retina After Sodium Iodate Injection in Mice,” Vision Res. 37(14):1859-1865 (1997). [cited by applicant]
Obata, R. et al., “Retinal degeneration is delayed by tissue factor pathway inhibitor-2 in RCS rats and a sodium-odate-induced model in rabbits,” Eye 19:464-468 (2005). [cited by applicant]
Ohtaka, K. et al., “Protective Effect of Hepatocyte Growth Factor Against Degeneration of the Retinal Pigment Epithelium and Photoreceptor in Sodium Iodate-Injected Rats,” Curr. Eye Res. 31:347-355 (2006). [cited by applicant]
Ross, R. J. et al., “Immunological protein expression profile in Ccl2/Cx3cr1 deficient mice with lesions similar to age-related macular degeneration,” Exp. Eye Res. 86(4):675-683 (2008). [cited by applicant]
Sarks, J. et al., “Evolution of reticular pseudodrusen,” Br. J. Ophthalmol. 95:979-985 (2011). [cited by applicant]
Spencer, D. B. et al., “In vivo imaging of the immune response in the eye,” Semin. Immunopathol. 30:179-190 (2008). [cited by applicant]
Tanaka, M. et al., “Third-Order Neuronal Responses Contribute to Shaping the Negative Electroretinogram in Sodium Iodate-Treated Rats,” Curr. Eye Res. 30:443-453 (2005). [cited by applicant]
Zeng, X-X et al., “Labelling of retinal microglial cells following an intravenous injection of a fluorescent dye into rats of different ages,” J. Anat. 196:173-179 (2000). [cited by applicant]
Zhao, X. et al., “Patches of RPE Loss Can Be Detected In Vivo In The Rat Eye Using Confocal Scanning Laser Ophthalmoscopy,” 2011 ARVO Annual Meeting, Abstract of Program#/Poster# 969/A161, 2 pages (May 1, 2011). [cited by applicant]
Zweifel, S. A. et al., “Prevalence and Significance of Subretinal Drusenoid Deposits (Reticular Pseudodrusen) in Age-Related Macular Degeneration,” Ophthalmology 117(9):1775-1781 (2010). [cited by applicant]
Zweifel, S. A. et al., “Reticular Pseudodrusen Are Subretinal Drusenoid Deposits,” Ophthalmology 117(2):303-312 (2010). [cited by applicant]
Rodrigues, E.B. et al., “The Use of Vital Dyes in Ocular Surgery”, Survey of Ophthalmology, 2009, vol. 54, No. 5, pp. 676-617. [cited by applicant]
Kiuchi, K. et al., “Morphologic Characteristics of Retinal Degeneration Induced by sodium Iodate in Mice”, Current eye Research, 2002, vol. 25, No. 6, pp. 373-379. [cited by applicant]
Xu,Z. et al. “The Association for Research in Vision and Ophthalmology”, Annual Meeting 2001. [cited by applicant]